News, trends, and stories from the synthetic biology industry

Hi all,

There's a red hot area that's about to explode onto the synthetic biology scene. No longer are we limited to using chemical synthesis for making DNA. A new generation of startups are using biology's power by engineering enzymes to synthesize As, Cs, Ts and Gs. Molecular Assemblies was one of the first to develop an enzymatic DNA synthesis technology capable of powering new products from therapeutics, precision diagnostics, chemicals, materials, food and more. I'm proud that this week's newsletter is sponsored by my good friend Mike Kamdar at Molecular Assemblies. You can check out more about what they're doing on their website.

SynBioBeta is hiring a new Head of Sales and I'd love for you to put the word out in your network to come join our awesome team. You can see the job posting here. We are also looking for a graphic designer. If you want to post a job in my newsletter, please contact us.
 

Here are some of my latest articles from Forbes:

An interview with Lattice Automation Co-founder Doug Densmore. “We’re taking the tenants in big biology; abstraction, modularity, standards, composition; and making that discipline computational,” says Densmore.

Cell-free technology comes of age: BioBits is changing the way we teach biology. The safety and accessibility of BioBits is hard to beat. Biology is an expensive field to dabble in, but $100 is enough to provide a classroom’s worth of BioBits kits.

One company was the first to produce a key component of the Covid-19 PCR test. And it has now provided 52 million tests. Roman Terrill is proud of how the scientific community has come together this year - putting public health at the forefront.

In COVID-19 news, a vaccine against the disease is in sight, with the announcement of the first interim results in large-scale trials showing the Pfizer/BioNTech candidate is 90% effective, according to the companies. Pfizer’s vaccine use messenger-RNA, or mRNA, technology, which uses genetic material to cause the body to create a protein from the virus; the immune system then recognizes the virus and learns to attack.
 

In case you missed our event "Optimize Your Workflow: Bottlenecks & Solutions in the Design, Build, & Test Phase", you can watch the recording now! You can also join the EMnetik 24 early access program here, it's a benchtop nucleic acid cleanup device arriving in 2021.


In funding news, Ambrx, a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, raised $200 million, and Cytek Biosciences, a leading provider of cell analysis instrumentation and solutions, closed a $120 million Series D funding round.

For the first time ever, SynBioBeta is offering incredible Early Black Friday Deals! We have awesome events lined up and this may be your chance to join some of the most exclusive conversations and networking events in the synthetic biology space! Click here and be the first to receive access to our Early Black Friday Deals!

Regards,
John

Latest News

The xenobot future is coming—start planning now (WIRED)

 

Duke, UNC researchers tackle synthetic biology through $7.5M Pentagon grant (WRAL TechWire)
 

'The biological event of our lives': Boston biotech unicorn dives into mass coronavirus testing (WBUR)

Evidence is mounting that gene-editing human embryos can have destructive side effects (Future Human)

eGenesis announces collaboration with leading academic medical center to conduct in vivo testing of pancreatic islet cell xenotransplants (Press release)

Synthace and Ipsen partner to accelerate novel therapeutic development through automation (Press release)
 

Eli Lilly’s antibody treatment gets Emergency F.D.A. Approval (NYT)

 

Scientists just stored 52 pages of Mozart in DNA (Future Human)

 

Stanford engineers have developed a genetic microlab that can detect COVID-19 in minutes


Intellia Therapeutics doses first patient in landmark CRISPR/Cas9 clinical trial of NTLA-2001 for the treatment of transthyretin amyloidosis (Press release)

Scientists identify synthetic mini-antibody to combat COVID-19 (EMBL)

Who's hiring?

Senior Director: Conagen – Bedford, MA


Graphic Designer: SynBioBeta (contractor)

Head of Sales: SynBioBeta – Pleasant Hill, CA

Applications Analyst (LIMS): Geltor – San Leandro, CA

Business Systems Administrator: Geltor – San Leandro, CA

Marketing Communications Manager/Sr. Manager: DNA Script – South San Francisco or Paris, France
 

Senior Research Associate, Strain Engineering: Flagship Pioneering – Cambridge, MA

 

Synbionik – Germany, Multiple Positions

Codexis – Redwood City, CA, Multiple Positions

AbSci – Vancouver, WA, and Boston, MA Multiple Positions

 

Postdoctoral Research Fellow (Gene Delivery): John A. Burns School of Medicine – Honolulu, HI

 

Scientist, Synthetic Biology: Empress Therapeutics, Inc. – Cambridge, MA

Scientist: Palamedrix – San Diego, CA


Senior Scientist, Biochemistry: Inscripta – Pleasanton, CA

Product Manager (Synthetic Biology): Twist Bioscience – San Francisco, CA

Director, Bioinformatics: LifeMine – Cambridge, MA

Staff Engineer, Process Development: Inscripta – San Diego, CA
 

Molecular Biology Team Lead: Slone Partners – San Carlos, CA

 

COVID Test Processor: OpenCell – Jersey, UK

 

Biochip Design Engineer: Analog Devices – Boston, MA

 

Postdoctoral fellow: GartonLab – Toronto, Canada

 

Postdoctoral Research Fellow (Gene Delivery): John A. Burns School of Medicine – Honolulu, HI

 

Scientist, Synthetic Biology: Empress Therapeutics, Inc. – Cambridge, MA

 

 

Feature your job here